Pursuing the curative blueprint for early myeloma

Blood

Volumn 122, Issue 4, 2013, Pages 486-490

  Roschewski, Mark ^a   Korde, Neha ^a   Wu, S Peter ^a   Landgren, Ola ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; LENALIDOMIDE;

ARTICLE; BONE MARROW CELL; COMORBIDITY; DISEASE COURSE; DISEASE ERADICATION; DISEASE SURVEILLANCE; EARLY INTERVENTION; FOLLOW UP; HUMAN; MICROENVIRONMENT; MINIMAL RESIDUAL DISEASE; MOLECULAR IMAGING; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATHOGENESIS; PATIENT SELECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SOMATIC HYPERMUTATION; TUMOR VOLUME; WHOLE BODY MRI; BIOLOGICAL MODEL; DECISION MAKING; GENETICS; METHODOLOGY; PATHOLOGY;

CHOICE BEHAVIOR; DISEASE PROGRESSION; HUMANS; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; PATIENT SELECTION; REMISSION INDUCTION;

EID: 84886879485     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-01-481291     Document Type: Article

References (30)

1. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008; 111(5): 2516-2520.
2. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008; 111(5): 2521-2526.
3. Barlogie B, Attal M, Crowley J., et al. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. J Clin Oncol. 2010; 28(7): 1209-1214.
4. Rajkumar SV, Gahrton G, Bergsagel PL. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood. 2011; 118(12): 3205-3211.
5. Landgren O, Kyle RA, Pfeiffer R.M., et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009; 113(22): 5412-5417.
6. Weiss BM, Abadie J, Verma P., Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009; 113(22): 5418-5422.
7. Kyle RA, Durie BGM, Rajkumar SV, et al.; International Myeloma Working Group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010; 24(6): 1121-1127.
8. Hillengass J, Kilk K, Listl K., et al. Over 30% of smoldering myeloma patients have tumor cell bone marrow infiltration patterns similar to multiple myeloma: a large (n=544) clinical study using whole-body MRI [abstract]. Blood (ASH Annual Meeting Abstracts). 2012; 120(21). Abstract 2911.
9. López-Corral L., Gutiérrez NC, Vidriales M.B., et al. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clin Cancer Res. 2011; 17(7): 1692-1700.
10. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976; 194(4260): 23-28.
11. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012; 12(5): 335-348.
12. Egan JB, Shi CX, Tembe W, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood. 2012; 120(5): 1060-1066.
13. Keats JJ, Chesi M, Egan J.B., et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012; 120(5): 1067-1076.
14. Walker BA, Wardell CP, Melchor L, et al. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood. 2012; 120(5): 1077-1086.
15. Ghobrial IM. Myeloma as a model for the process of metastasis: implications for therapy. Blood. 2012; 120(1): 20-30.
16. Kastritis E, Terpos E, Moulopoulos L., et al. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Leukemia. 2013; 27(4): 947-953.
17. Pérez-Persona E., Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007; 110(7): 2586-2592. (Pubitemid 47523182)
18. Dispenzieri A, Kyle RA, Katzmann J.A., et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008; 111(2): 785-789.
19. Cherry BM, Korde N, Kwok M., et al. Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study [published online ahead of print January 11, 2013]. Leuk Lymphoma.
20. Usmani SZ, Sawyer J, Rosenthal A., et al. Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. Blood. 2013; 121(23): 4753-4757.
21. Mateos M-V, López-Corral L, Hernández M, et al. Smoldering multiple myeloma (SMM) at high-risk of progression to symptomatic disease: a phase III, randomized, multicenter trial based on lenalidomide-dexamethasone (Len-Dex) as induction therapy followed by maintenance therapy with Len alone vs no treatment [abstract]. Blood (ASH Annual Meeting Abstracts). 2011; 118(21). Abstract 991.
22. LoRusso PM, Canetta R, Wagner J.A., et al. Accelerating cancer therapy development: the importance of combination strategies and collaboration. Summary of an Institute of Medicine workshop. Clin Cancer Res. 2012; 18(22): 6101-6109.
23. Jakubowiak AJ, Dytfeld D, Griffith K.A., et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012; 120(9): 1801-1809.
24. Korde N, Zingone A, Kwok M., et al. Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients [abstract]. Blood (ASH Annual Meeting Abstracts). 2012; 120(21). Abstract 732.
25. Paiva B, Vidriales MB, Cerveró J, et al; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008; 112(10): 4017-4023.
26. Paiva B, Martinez-Lopez J, Vidriales M.B., et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol. 2011; 29(12): 1627-1633.
27. Sarasquete ME, García-Sanz R, González D, et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica. 2005; 90(10): 1365-1372. (Pubitemid 41503652)
28. Walker R, Barlogie B, Haessler J., et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol. 2007; 25(9): 1121-1128. (Pubitemid 46596765)
29. Hillengass J, Ayyaz S, Kilk K., et al. Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma. Haematologica. 2012; 97(11): 1757-1760.
30. Bartel TB, Haessler J, Brown T.L., et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009; 114(10): 2068-2076.